Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Molecular Partners AG (MOLN)Business Wire • 07/14/22
INVESTOR ALERT: Molecular Partners AG Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MOLNBusiness Wire • 07/14/22
EQUITY ALERT: Rosen Law Firm Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action – MOLNBusiness Wire • 07/13/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Partners AG - MOLNPRNewsWire • 05/11/22
Molecular Partners to Participate in Upcoming Healthcare Investor ConferencesGlobeNewsWire • 05/11/22
Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech AssociationGlobeNewsWire • 05/03/22
Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidateMarket Watch • 04/27/22
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional DataBenzinga • 04/27/22
Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings CallGlobeNewsWire • 04/26/22
Molecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022GlobeNewsWire • 04/23/22
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General MeetingGlobeNewsWire • 04/13/22
Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology ResearchGlobeNewsWire • 03/24/22
Molecular Partners AG (MOLN) CEO Patrick Amstutz on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/16/22
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021GlobeNewsWire • 03/15/22
Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19Benzinga • 02/10/22
Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19GlobeNewsWire • 02/10/22